CareDx, Inc
NASDAQ:CDNAMedical - Diagnostics & Research
+$1.19 today
- Market cap
- $3.91B
- Beta
- 2.48
- P/E (TTM)
- -154.0
- EPS (TTM)
- -$0.16
Volume 0.54M
Average 0.74M
CDNA Net Income
Bottom-line profit, the starting point for calculating cash from operations.
CareDx, IncNASDAQ: CDNA
Net Income · Q2 FY2026 · quarter ended Jun 2026
Net income turns positive
Q2 FY2026 net income was $110.64M, compared with -$8.57M a year earlier. Trailing-twelve-month net income was $111.01M. Over 3 fiscal years it compounded at -34.7% a year.
Context
- Net income amounted to 5.6% of revenue in FY2025, down 10.1 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 6 analysts of $94.5M (+542.6%) for the fiscal year ending Dec 2026, a step up from the -140.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $110.64M+3838.6% QoQ
- Last fiscal yearDec 2025
- -$21.35M-140.6% YoY
- LTMJun 2026
- $111.01M+90.9% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +1391.3% | +736.6% | -654.7 pp |
| 1 year | -140.6% | +542.6% | +683.2 pp |
| 3-year CAGR | -34.7% | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (21.35M) USD
- Year-over-year change
- -140.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (21.35M) | -140.6% |
| FY2024 | 2024-12-31 | 52.55M | +127.6% |
| FY2023 | 2023-12-31 | (190.28M) | -148.4% |
| FY2022 | 2022-12-31 | (76.61M) | -149.9% |
| FY2021 | 2021-12-31 | (30.66M) | — |
Net Income vs competitors
How CDNA compares with its peers on the latest reported figures
- CDNA's LTM Jun 2026 net income of $111.01M is the 5th largest of the 8 companies compared; the peer median is $74.56M.
- Its year-over-year change of +90.9% is the 3rd highest of 7, against a peer median of +43.8%.
- Net income amounts to 24.2% of revenue for CDNA, versus a peer median of 20.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $409.32M | +9.6% | +0.1% | 19.5% | |
| LTM Mar 2026 | $399.9M | +294.4% | +48.4% | 48.2% | |
| LTM Jun 2026 | $192.35M | -24.0% | -27.6% | 7.1% | |
| LTM Jun 2026 | $114.48M | +334.7% | — | 20.4% | |
| LTM Jun 2026 | $111.01M | +90.9% | -34.7% | 24.2% | |
WGSGeneDx Holdings Corp. | LTM Jun 2026 | $106.36M | -7664.5% | -66.3% | 23.4% |
| LTM Mar 2026 | $74.56M | +78.1% | — | 23.3% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $37.71M | — | — | 9.5% |
| Peer median (excluding CDNA) | $74.56M | +43.8% | -13.7% | 20.4% | |
Competitors are the stored peer set for CDNA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.66M) | (76.61M) | (190.28M) | 52.55M | (21.35M) |
| Depreciation & Amortization | 11.89M | 16.01M | 19.82M | 19.76M | 20.42M |
| Deferred Income Tax | 0 | 0 | 566K | (187K) | 17K |
| Stock-Based Compensation | 36.08M | 46.55M | 49.09M | 66.41M | 34.86M |
| Change in Working Capital | (40.97M) | (14.22M) | 106.03M | (102.31M) | 3.81M |
| Accounts Receivables | (24.42M) | (6.66M) | 16.02M | (13.74M) | 22.52M |
| Inventory | (6.93M) | (2.86M) | 54K | (1.02M) | (4.96M) |
| Accounts Payables | 1.79M | (2.05M) | 2.9M | (5.11M) | 808K |
| Other Working Capital | (11.42M) | (2.64M) | 87.06M | (82.44M) | (14.56M) |
| Other Non-Cash Items | 4.37M | 3.03M | (3.61M) | 1.83M | 4.28M |
| Operating Cash Flow | (19.29M) | (25.24M) | (18.39M) | 38.05M | 42.03M |
| Capital Expenditures | (20.26M) | (24.33M) | (9.24M) | (6.48M) | (5.91M) |
| Acquisitions (Net) | (15.43M) | (610K) | (6.68M) | 0 | 0 |
| Purchases of Investments | (5.5M) | (315.15M) | (201.17M) | (160.29M) | (145.93M) |
| Sales of Investments | 88.91M | 111.59M | 256.04M | 166.92M | 154.67M |
| Other Investing Activities | 0 | 0 | 1.5M | (634K) | 0 |
| Investing Cash Flow | 47.71M | (228.5M) | 40.45M | (483K) | 2.16M |
| Debt Repayment | (66K) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 188.86M | 0 | 0 | 0 | 8M |
| Common Stock Repurchased | 0 | (642K) | (27.54M) | (522K) | (87.77M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.15M) | (3.89M) | (2.07M) | (5.08M) | (13.62M) |
| Financing Cash Flow | 185.64M | (4.54M) | (29.61M) | (5.61M) | (93.39M) |
| Effect of Forex Changes | (303K) | 23K | (112K) | 532K | (90K) |
| Net Change in Cash | 213.76M | (258.25M) | (7.66M) | 32.49M | (49.29M) |
| Free Cash Flow | (39.55M) | (49.57M) | (27.63M) | 31.56M | 36.12M |
CareDx, Inc
NASDAQ:CDNA
Intrinsic Alpha fair value
Locked
Current Price
$74.44
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.